Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9658593 | 0.81 | MTNR1A (0.33) | MTNR1AMTNR1BKDM4E | |
| SCHEMBL9658596 | 0.81 | MTNR1A (0.33) | MTNR1AMTNR1BKDM4E | |
| SCHEMBL11092663 | 0.79 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL11095942 | 0.79 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL11092667 | 0.79 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL7191918 | 0.77 | — | — | |
| SCHEMBL16297599 | 0.77 | — | — | |
| SCHEMBL30881128 | 0.77 | — | — | |
| SCHEMBL11107958 | 0.75 | — | — | |
| SCHEMBL19435722 | 0.74 | GAA (0.46) | ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | MTNR1A 4001/4885MTNR1B 4306/4885ALDH1A1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.